Ambit Biosciences and Astellas Announce Upcoming Presentation of AC220 Data at the 16th Annual Congress of the European Hematology Association
San Diego and Tokyo (ots/PRNewswire) - Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that the first presentation of interim data from a global multi-center Phase 2 study evaluating the investigational drug AC220, a potent and selective FLT3 inhibitor. The data will be presented in an oral ...
mehr